MedTrace Logo

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

NCT03290794 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-06-09

No results posted yet for this study

Summary

The proposed regulatory post-marketing surveillance (PMS) study will be planned to collect the safety data of aflibercept intravitreal injection in patients with wet Age-related Macular Degeneration (AMD) in real-life treatment practice

The primary objective is:

\- To collect safety data in wet AMD patients treated with intravitreal aflibercept injection

The secondary objective is:

\- To determine how disease activity is monitored including type and frequency of ocular tests and frequency of injections

Conditions

Interventions

DRUG

Aflibercept (Eylea, BAY86-5321)

Intravitreal Aflibercept as prescribed by the treating Physician

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-14
Primary Completion
2022-11-25
Completion
2023-05-26

Countries

  • India

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03290794 on ClinicalTrials.gov